Heterologous SARS-CoV-2 booster vaccine for individuals with hematological malignancies after a primary SARS-CoV-2 mRNA vaccine series

Amy C Sherman; Simon D van Haren; Ella Borberg; Zoe Swank; Muneerah Aleissa; Alexandra Tong; Rebecca Rooks; Urwah Kanwal; Hannah Levine; Bridget Yates; Natalie Izaguirre; Kevin Ryff; Sanya Thomas; Lindsey Parisi; Xiaofang Li; David R Walt; Ofer Levy; Stephen R Walsh; Nicolas C Issa; Lindsey R Baden

doi:10.1016/j.vaccine.2024.05.081

Heterologous SARS-CoV-2 booster vaccine for individuals with hematological malignancies after a primary SARS-CoV-2 mRNA vaccine series

Vaccine. 2024 Sep 17;42(22):126054. doi: 10.1016/j.vaccine.2024.05.081. Epub 2024 Jun 10.

Authors

Amy C Sherman¹, Simon D van Haren², Ella Borberg³, Zoe Swank³, Muneerah Aleissa⁴, Alexandra Tong⁵, Rebecca Rooks⁶, Urwah Kanwal⁵, Hannah Levine⁵, Bridget Yates⁵, Natalie Izaguirre⁵, Kevin Ryff⁷, Sanya Thomas², Lindsey Parisi⁵, Xiaofang Li⁵, David R Walt⁸, Ofer Levy⁹, Stephen R Walsh¹⁰, Nicolas C Issa¹¹, Lindsey R Baden¹¹

Affiliations

¹ Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA; Dana-Farber Cancer Institute, Boston, MA, USA; Precision Vaccines Program, Department of Pediatrics, Boston Children's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA. Electronic address: [email protected].
² Precision Vaccines Program, Department of Pediatrics, Boston Children's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
³ Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA; Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, USA.
⁴ Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA; Dana-Farber Cancer Institute, Boston, MA, USA; Department of Pharmacy Practice, College of Pharmacy, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia.
⁵ Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA.
⁶ Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA; Emory School of Medicine, Atlanta, GA, USA.
⁷ Precision Vaccines Program, Department of Pediatrics, Boston Children's Hospital, Boston, MA, USA.
⁸ Harvard Medical School, Boston, MA, USA; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA; Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, USA.
⁹ Precision Vaccines Program, Department of Pediatrics, Boston Children's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Broad Institute of MIT & Harvard, Cambridge, MA, USA.
¹⁰ Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
¹¹ Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA; Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.

PMID: 38862310
DOI: 10.1016/j.vaccine.2024.05.081

Abstract

Heterologous COVID-19 vaccine boosters have not been evaluated for patients with hematological malignancies. A Novavax booster was administered for 56 individuals with hematological malignancies who had received a primary COVID-19 series and prior boosters with mRNA vaccines only. Blood specimens were obtained at baseline (pre-vaccine), 28 days, and 168 days after vaccination with the Novavax booster. The median fold change of anti-Spike IgG was 1.02 (IQR 0.79, 1.3) between baseline and Day 28. Circulating Spike protein-specific B cells increased 1.4-fold at Day 28 (p < 0.05). Increases in antibody and T cell responses were modest without significance, with a waning of humoral and cellular responses at 168 days after vaccination.

MeSH terms

Adult
Aged
Antibodies, Viral* / blood
Antibodies, Viral* / immunology
B-Lymphocytes / immunology
COVID-19 Vaccines* / administration & dosage
COVID-19 Vaccines* / immunology
COVID-19* / immunology
COVID-19* / prevention & control
Female
Hematologic Neoplasms* / immunology
Humans
Immunity, Humoral
Immunization, Secondary*
Immunoglobulin G* / blood
Male
Middle Aged
SARS-CoV-2* / immunology
Spike Glycoprotein, Coronavirus* / immunology
T-Lymphocytes / immunology
Vaccines, Synthetic / administration & dosage
Vaccines, Synthetic / immunology
mRNA Vaccines

Substances

COVID-19 Vaccines
Antibodies, Viral
Spike Glycoprotein, Coronavirus
Immunoglobulin G
mRNA Vaccines
spike protein, SARS-CoV-2
Vaccines, Synthetic